Kynaston H - Search Results

1

The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer.

Noble SM, Garfield K, Lane JA, Metcalfe C, Davis M, Walsh EI, Martin RM, Turner EL, Peters TJ, Thorn JC, Mason M, Bollina P, Catto JWF, Doherty A, Gnanapragasam V, Hughes O, Kockelbergh R, Kynaston H, Paul A, Paez E, Rosario DJ, Rowe E, Oxley J, Staffurth J, Neal DE, Hamdy FC, Donovan JL. Noble SM, et al. Among authors: kynaston h. Br J Cancer. 2020 Sep;123(7):1063-1070. doi: 10.1038/s41416-020-0978-4. Epub 2020 Jul 16. Br J Cancer. 2020. PMID: 32669672 Free PMC article. Clinical Trial.

2

Substitution cystoplasty for intractable interstitial cystitis.

Hughes OD, Kynaston HG, Jenkins BJ, Stephenson TP, Vaughton KC. Hughes OD, et al. Among authors: kynaston hg. Br J Urol. 1995 Aug;76(2):172-4. doi: 10.1111/j.1464-410x.1995.tb07668.x. Br J Urol. 1995. PMID: 7663907

3

Gangrenous cystitis in a paraplegic patient. Case report.

Hughes OD, Brough SJ, Kynaston HG, Jenkins BJ. Hughes OD, et al. Among authors: kynaston hg. Paraplegia. 1994 Sep;32(9):622-3. doi: 10.1038/sc.1994.98. Paraplegia. 1994. PMID: 7997342 No abstract available.

4

Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer.

Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Shelley MD, et al. Among authors: kynaston h. Cochrane Database Syst Rev. 2000;2000(4):CD001986. doi: 10.1002/14651858.CD001986. Cochrane Database Syst Rev. 2000. PMID: 11034738 Free PMC article. Review.

5

The prevalence and predictors of psychological distress in patients with early localized prostate cancer.

Bisson JI, Chubb HL, Bennett S, Mason M, Jones D, Kynaston H. Bisson JI, et al. Among authors: kynaston h. BJU Int. 2002 Jul;90(1):56-61. doi: 10.1046/j.1464-410x.2002.02806.x. BJU Int. 2002. PMID: 12081771

6

Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.

Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M. Shelley MD, et al. Among authors: kynaston h. Cochrane Database Syst Rev. 2003;(3):CD003231. doi: 10.1002/14651858.CD003231. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2015 Nov 07;(11):CD003231. doi: 10.1002/14651858.CD003231.pub2 PMID: 12917955 Updated. Review.

7

Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.

Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Shelley MD, et al. Among authors: kynaston h. BJU Int. 2004 Mar;93(4):485-90. doi: 10.1111/j.1464-410x.2003.04655.x. BJU Int. 2004. PMID: 15008714 Review.

8

Hepatocyte growth factor/scatter factor and prostate cancer: a review.

Hurle RA, Davies G, Parr C, Mason MD, Jenkins SA, Kynaston HG, Jiang WG. Hurle RA, et al. Among authors: kynaston hg. Histol Histopathol. 2005 Oct;20(4):1339-49. doi: 10.14670/HH-20.1339. Histol Histopathol. 2005. PMID: 16136515 Review.

9

Com-1/p8 acts as a putative tumour suppressor in prostate cancer.

Jiang WG, Davies G, Martin TA, Kynaston H, Mason MD, Fodstad O. Jiang WG, et al. Among authors: kynaston h. Int J Mol Med. 2006 Nov;18(5):981-6. Int J Mol Med. 2006. PMID: 17016631

10

Does the PGC-1/PPARgamma pathway play a role in Com-1/p8 mediated cell growth inhibition in prostate cancer?

Jiang WG, Davies G, Kynaston H, Mason MD, Fodstad O. Jiang WG, et al. Among authors: kynaston h. Int J Mol Med. 2006 Dec;18(6):1169-75. Int J Mol Med. 2006. PMID: 17089023

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

162 results

Search Page

Filters